← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Teriparatide

FDA approved · Rx

Parathyroid hormone analog

Also known as: Forteo, Bonsity, PTH 1-34, Teriparatida, Teriparatidum, 1-34-Human PTH, Human PTH (1-34), ZT-034, LY 333334, TERIPARATIDE RECOMBINANT HUMAN

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 182 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Teriparatide is a synthetic version of the first 34 amino acids of human parathyroid hormone, the active portion of the natural hormone. Given intermittently, it is thought to stimulate bone-forming cells more than bone-resorbing cells, which builds new bone rather than only slowing bone loss. It is sold under brand names including Forteo and Bonsity.

What the evidence shows

Automatic summaryHuman trials

Teriparatide is FDA-approved for treating osteoporosis in people at high risk of fracture, including postmenopausal women, men, and people with glucocorticoid-induced osteoporosis. It is backed by a large body of human research, with 182 registered trials reaching Phase 4 and over 3,000 published papers, though uses outside its approved indications are less well established.

Key facts

Molecular formula
C181H291N55O51S2
Molecular weight
4118 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

182registered studies
Phase 4most advanced phase
67completed (sample)
4recruiting (sample)

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

Phase 2CompletedNCT02049866

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

Phase 4CompletedNCT01153425

Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Phase 3CompletedNCT01896011

Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese

UnknownNCT02166437

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

3,067papers referencing Teriparatide

Osteoporosis.

Lancet2019

Clinical Practice. Postmenopausal Osteoporosis.

N Engl J Med2016

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

J Bone Miner Res2014

Romosozumab in postmenopausal women with low bone mineral density.

N Engl J Med2014

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.